Driven by product innovation and an aging population, the market for US urological devices will grow at a modest rate through 2029 despite the impact of the ongoing COVID-19 pandemic. Going forward, favorable demographic trends, an increasing prevalence of obesity, and the growing availability of less invasive treatment options will support the growth of urology procedure volumes. Moreover, the continued shift toward value-based health care in the US will drive demand for minimally invasive treatments that not only provide improved efficacy, but also reduced postoperative pain and shorter recovery periods.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in the US across a 10-year period.
The COVID-19 pandemic will negatively impact the US urological device market.
Which types of procedures and device segments will be most impacted?
At what pace is the urological device market expected to recover?
Some market segments are being negatively impacted by product safety concerns.
Which market segments are being impacted by safety concerns?
In which countries are these markets highly affected by these concerns, and in which countries are these markets less affected?
Emerging technologies and innovative products will grow in popularity at the expense of competing treatment options.
How will the growing preference for ureteroscopy affect the stone management device market?
What role does strong clinical evidence play in the adoption of new technologies?
Minimally invasive treatment volumes will grow strongly.
What factors contribute to the increase of minimally invasive treatments?
How have minimally invasive treatment options changed the BPH device market?
Which market segments will see the greatest adoption of minimally invasive treatments?
FDA approval, and subsequent reimbursement coverage, will drive procedure growth.
Which procedures will be impacted by FDA approval over the forecast period?
How will reimbursement shift the competitive landscape?
- Urological Devices - Market Insights - United States
Author(s): Benny Jacob, MS
Benny Jacob is an analyst on the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in the ENT Devices market. Benny has a background that covers Data Science, Systems Neuroscience and Bioinformatics. Benny has a Masters' Degree in Computational Biology from Carnegie Mellon University, Pittsburgh and a Bacherlor's Degree in Biotechnology from Manipal Institute of Technology, Manipal (India).